Kornimate/medical-research-clean huggingface dataset:
digoxin withdrawal in stable heart failure

Conditions: Heart Failure

Summary: heart failure is a chronic condition in which the heart fails to function as a pump to move blood around the body. this sets up a complex physiologic response to compensate, which include activation of many hormonal mechanisms which result in fluid accumulation. in recent years, medications to block the hormonal response to heart failure are given as standard drugs, and these include ace inhibitors, and beta blockers. mortality is reduced with these medications, as well as symptoms improved. medications that were traditionally used in heart failure include diuretics, which cause fluid loss, and digoxin, which causes the heart to pump harder. these medications were introduced before clinical trials as we know them now were run. since the introduction of ace inhibitors and beta blockers, it is not clear whether there is still a role for digoxin. in this study, we plan to withdraw digoxin from patients with stable heart failure in normal rhythm, taking stable doses of ace inhibitors and beta blockers, in a closely monitored environment and watch for the effect of this on heart failure.


Eligibility criteria:
inclusion criteria: 1. over the age of 18 years 2. in sinus rhythm at the time of randomisation 3. have a lvef \ 60 mm or \>34 mm/m2 4. are receiving ace inhibitor, β-blocker and diuretic therapy at the optimal doses. 5. has been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. the dose of digoxin must remain stable for at least 2 weeks prior to randomisation. 6. documented, stable heart failure. must have at least 1 of the following: * hospitalised with a discharge diagnosed of heart failure in the last 6 months * evidence of pulmonary congestion on chest x-ray * evidence of heart failure on echocardiogram * evidence of heart failure on ecg 7. willing and able to provide informed consent exclusion criteria: 1. systolic bp \>160mmhg or \<90mmhg 2. diastolic bp \>95mmhg 3. uncorrected primary valvular disease 4. active myocarditis 5. obstructive or restrictive cardiomyopathy 6. exercise capacity limited by other factors not including dyspnoea 7. myocardial infarction within the previous 6 months 8. stroke within the previous 12 months 9. hospitalisation within one month of randomisation 10. a history of supraventricular arrhythmia or sustained ventricular arrhythmia 11. claudication 12. severe primary pulmonary (vc \<1.5l), renal or hepatic disease

Keywords: heart failure digoxin withdrawal
fibromyalgia: impact of self-knowledge on well-being

Conditions: Fibromyalgia

Summary: the goal of this observational study is to evaluate the impact of self-knowledge training on the well-being of individuals with fibromyalgia. the main questions it aims to answer are: does self-knowledge training improve participants' perceived quality of life? does self-knowledge training influence the way participants manage their fibromyalgia symptoms? participants will: take part in a structured self-knowledge intervention based on the enneagram framework. complete validated questionnaires before and after the intervention to assess their well-being. provide qualitative feedback on their experience with the training. this study will help understand whether self-awareness strategies can be integrated into non-pharmacological approaches for fibromyalgia management.


Eligibility criteria:
inclusion criteria: * diagnosis of fibromyalgia * age ≥ 18 years * ability to understand and provide informed consent exclusion criteria: * cognitive impairment that prevents comprehension of the intervention

Keywords: fibromyalgia self-knowledge quality of life enneagram
a personal nutrition advisor to assist remote dietary counselling for weight loss and maintenance

Conditions: Obesity

Summary: the purpose of the study is to assess the usability of the pna and satisfaction with the treatment within the framework of usual care remote nutritional counselling for glp-1-supported weight management and collect pilot data on its potential to support weight loss.

the global prevalence of obesity and overweight is increasing and persistently drives global mortality and morbidity.as overweight and obesity are the result of an imbalance between energy intake and energy use, achieving a negative energy balance build the foundation for weight loss. whilst dietary modification as a standalone procedure often fail in achieving or maintaining weight loss, the recent advent of supportive glucagon-like peptide-1 (glp-1) based pharmacotherapies have greatly changed the landscape.dietary counselling help people on glp-1 based treatment reaching their individual weight goals and continued reimbursement of medication costs. however, nutritional advice provided by dietitians is often generic, not sufficiently aligned to individual weight loss trajectories. the "personal nutrition advisor" (pna) is a decision support tool which is built upon an interpretable weight prediction model based on the energy balance equation (energy intake is a function of recorded dietary intake and a latent part dependent on observed weight changes, whereas energy expenditure is a function of weight and physical activity). food, weight- and activity records captured using a smartphone application represent input data to the model. output of the model is the predicted body weight trajectory alongside with personalized recommendations to reach a pre-defined target weight. integrating the pna into a remote dietary counselling programme, in which certified dietitians deliver nutritional and lifestyle coaching via an application, has the potential to improve treatment satisfaction and efficacy. therefore, the purpose of the study assess the usability of the pna and satisfaction with the treatment within the framework of usual care remote nutritional counselling for glp-1-supported weight management and collect pilot data on its potential to support weight loss.

Eligibility criteria:
inclusion criteria: * written informed consent * receiving glp-1-based pharmacotherapy in combination with remote nutritional counselling * achieved weight loss of ≥5 (for baseline bmi 28-35 kg/m2) or ≥7% (for baseline bmi≥35kg/m2) after 4 months of glp-1 based therapy (1st milestone) exclusion criteria: * inability to give written informed consent * any physical or psychological disease or condition likely to interfere with the normal conduct of the study and interpretation of the study results * self-reported pregnancy, planed pregnancy within next 3 months or breast-feeding * concomitant participation in another trial that interferes with the normal conduct of the study and interpretation of the study results * not proficient in german

Keywords: nutritional counselling personalised nutrition dietary advice usability
a study evaluating efruxifermin in subjects with non-invasively diagnosed nonalcoholic steatohepatitis (nash)/metabolic dysfunction-associated steatohepatitis (mash) and nonalcoholic fatty liver disease (nafld)/metabolic dysfunction-associated steatotic liver disease (masld)

Conditions: NASH/MASH; NAFLD/MASLD

Summary: the aim of this study is to assess the safety and tolerability of efx compared to placebo in subjects with non-invasively diagnosed nash/mash and nafld/masld.


Eligibility criteria:
inclusion criteria: main study only: * males and non-pregnant, non-lactating females between 18 - 80 (between 19-80 in the republic of korea) years of age inclusive, on the day of signing informed consent * previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes * suspected or confirmed diagnosis of nash/mash or nafld/masld or non-invasively diagnosed nash/mash or nafld/masld open-label rollover * prior participation in a previous akero phase 2 study exclusion criteria: * other causes of liver disease based on medical history and/or liver histology and/or central laboratory results, including but not limited to: alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis \[pbc\], primary sclerosing cholangitis \[psc\], autoimmune hepatitis), drug induced hepatotoxicity, wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency * type 1 or unstable type 2 diabetes a reduced list of inclusion and exclusion criteria apply to participants in the open-label rollover extension. other inclusion and exclusion criteria may apply.
low versus high-intensity exercises in sarcopenia

Conditions: Sarcopenia

Summary: this study aims to compare the effect of high-intensity resistance exercises measured using the 10-repetition maximum versus low-intensity aerobic exercises on muscle performance, physical function and quality of life in chronic kidney patients with sarcopenia who recently recovered from covid-19 infection

sarcopenia is a prevalent chronic disease caused by aging and is characterized by a reduction in muscle strength and mass (barajas-galindo et al., 2021), and consequently deterioration in physical function and quality of life (gil et al., 2021; tsekoura et al., 2017). sarcopenia is associated with higher rates of stroke, frailty, (bikbov et al., 2020; go et al., 2004; levin et al., 2013), and mortality (ali \& kunugi, 2021). generally, there are numerous causes of sarcopenia, including chronic kidney diseases (ckd) (souza et al., 2017), environmental factors, inflammatory mediator's activation, physical inactivity, mitochondrial dysfunction, hormonal changes, and loss of neural junctions (walston, 2012). recently, sarcopenia had great attention, especially among patients with ckd who already suffer from increased catabolism, higher protein wasting, and other metabolic disorders and decreased functional reserve. additionality, the decline in physical function due to the deterioration of muscle mass, power, and strength could significantly decrease balance and increase the risk of falling in these populations (moorthi \& avin, 2017). after the pandemic of covid-19 and the mandatory quarantine of patients during the recovery period, ckd patients with sarcopenia who were infected with covid-19 will be forced to assume a more sedentary lifestyle which consequently magnifies all health risks (gérard et al., 2021; gil et al., 2021) jeopardize subjects vitality (morley et al., 2020; mousa et al., 2021) and increasing prevalence of sarcopenia (ali \& kunugi, 2021). exercise has been proposed as one of the solutions for sarcopenia-associated symptoms. as per a recent systematic review (barajas-galindo et al., 2021), resistance exercises alone or with other forms of exercises could be beneficial especially in improving anthropometric parameters and muscle performance. yet its specific effects on post-covid-19 ckd patients who have sarcopenia need further investigation. the aim of this study is to compare the effectiveness of high versus low-intensity exercises on muscle strength, and physical function in post-covid-19 patients with sarcopenia secondary to ckd.

Eligibility criteria:
inclusion criteria: * both sexes with age between 50 - 70 years old. * ckd stages (3 and 4) * infected by covid-19 and recovered (1 - 2 months) * score of 4 or more on sar-qol questionnaire * patients having had a medical prescription for physical rehabilitation. exclusion criteria: * patients infected again by -covid-19 * any serious inflammatory, neurological, or cardiovascular diseases. * chronic chest disease. * chronic inflammatory orthopedic disorders and rheumatoid arthritis. * mental impairments.
the role of probiotics ps128 in movement disorders

Conditions: Rett Syndrome; Tourette Syndrome; Tic Disorders

Summary: pediatric movement disorders comprise of a large number of different neurological diseases including rett syndrome (rtt) and tourette syndrome. studies in the literature as well as our preliminary reports showed that rett syndrome and tourette syndrome/tic disorders are associated with a dysbiosis of the gut microbiota compared to normal control. probiotic lactobacillus plantarum ps128 is a diet supplement that available for human consumption. probiotic lactobacillus plantarum ps128 had showed psychotropic effects such as ameliorate anxiety- and depression-like behaviors as well as altered the level of neurotransmitters such as dopamine in the brain in animal models, which might be through microbiota-gut-brain axis. therefore, the purpose of this study is to access the possible neurobehavior effects of probiotic lactobacillus plantarum ps128 in rett syndrome and tic disorders/tourette syndrome.

the study is a placebo-controlled double-blind randomized study, to determine the benefits of probiotic lactobacillus plantarum ps128 vs placebo on symptoms for tic disorders; and the symptoms, behavior, or cognition for rett syndrome. patients with the rett syndrome and tic disorders/tourette syndrome will be recruited into our study.the study period will last 4 months for rett syndrome patients, age one year-50years; while 2 months for tic disorders/tourette syndrome patient, age 5 years-18 years. the study will be performed in national taiwan university children hospital. the patients will have neuropsychological and gut microbiota evaluation before and at the end of the study. there will also be interim follow up evaluations each month after the patient start taking the probiotic or placebo.

Eligibility criteria:
inclusion criteria: * rett syndrome: * males and females who have classic or atypical rtt diagnosed under consensus criteria * age: 1-50 years * tic disorders: * males and females with clinical diagnosis * age: 8-18years * treatment naive 4 weeks prior to study * those with standard medications, dosage stable 4 weeks prior to study * aadc syndrome: * males and females with aadc diagnosis * age: 1-50 years exclusion criteria: * those who took probiotic or probiotic related product 4 weeks prior to the study or during the study * those who took antibiotic 4 weeks prior to the study * those showing poor compliance with any aspect of the study * those had adverse reactions to ps128

Keywords: rett syndrome tourette syndrome probiotic
microarray analysis of sinus samples from patients with and without chronic rhinosinusitis

Conditions: Maxillary Sinusitis

Summary: mucosal biopsies, endoscopically-guided brush samples of mucus, and a saline lavage taken from the maxillary sinuses of ten crs patients undergoing sinus surgery are analyzed using three microarrays in order to detect bacteria, fungi and viruses. ten control patients with normal sinuses will have the same samples taken. the hypothesis is that bacterial, fungal, and viral communities present in the maxillary sinus of patients with crs are significantly different from those patients with healthy sinuses, and that microorganisms identified in patients with or without crs will differ from previously published data obtained using other techniques.

mucosal biopsies, endoscopically-guided brush samples of mucus, and a saline lavage taken from the maxillary sinuses of ten crs patients undergoing sinus surgery are analyzed using three microarrays: 16s rrna phylochip (to detect bacteria), mycochip (to detect fungi) and virochip (to detect viruses). ten control patients with normal sinuses, as assessed by ct scan and a sinusitis-specific survey, will have the same samples taken. the hypothesis is that bacterial, fungal, and viral communities present in the maxillary sinus of patients with crs are significantly different from those patients with healthy sinuses, and that microorganisms identified in patients with or without crs will differ from previously published data obtained using other techniques. comparing diseased and control flora will provide insight into the relative contribution of each pathogen to crs and may guide the development of future therapies.

Eligibility criteria:
inclusion criteria (crs patients): * history of crs as defined as symptoms (nasal discharge, nasal obstruction, facial pain and/or hyposmia) for \>12 weeks despite therapy. * impaired crs-specific quality of life (snot-20 score \>1.5). * evidence of sinus disease on a ct scan (lund mackay score greater than or equal to 10). * patients with positive skin or rast testing to an inhalant allergen and/or aspirin hypersensitivity will be included. evidence of atopy is not required but will be recorded, along with serum ige levels, when available. inclusion criteria (control patients): * no history of crs * snot-20 score \<1.0 * no evidence of sinus disease on preoperative imaging exclusion criteria: * control patients with any evidence of crs, by history, survey, or imaging criteria would be excluded.

Keywords: chronic rhinosinusitis sinus disease allergy maxillary sinus microarray
validation of a universal cataract intelligence platform

Conditions: Cataract; Artificial Intelligence

Summary: this study established and validated a universal artificial intelligence (ai) platform for collaborative management of cataracts involving multi-level clinical scenarios and explored an ai-based medical referral pattern to improve collaborative efficiency and resource coverage.the datasets were labeled using a three-step strategy: (1) categorize slit lamp photographs into four separate capture modes; (2) diagnose each photograph as a normal lens, cataract or a postoperative eye; and (3) based on etiology and severity, further classify each diagnosed photograph for a management strategy of referral or follow-up. a deep residual convolutional neural network (cs-rescnn) was used for the image classification task. moreover, we integrated the cataract ai agent with a real-world multi-level referral pattern involving self-monitoring at home, primary healthcare, and specialized hospital services.


Eligibility criteria:
inclusion criteria: patients who underwent ophthalmic examination of the eye and recorded their ocular information in the primary healthcare center. exclusion criteria: the patients who cannot cooperate with the examinations.

Keywords: cataract artificial intelligence medical referral pattern
a study to investigate weight management with ly3841136 and tirzepatide (ly3298176), alone or in combination, in adult participants with obesity or overweight with type 2 diabetes

Conditions: Obesity; Overweight

Summary: the main purpose of this study, performed under the master protocol w8m-mc-cwmm (nct06143956), is to investigate the safety and efficacy of ly3841136 for chronic weight management alone or in combination with tirzepatide across a wide dose range in participants with type 2 diabetes. participation in the study will last about 64 weeks.


Eligibility criteria:
inclusion criteria: w8m-mc-laa2 * have a body mass index (bmi) of ≥27 kilograms per square meter (kg/m²) * have type 2 diabetes * have a hba1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (sglt2) inhibitor for at least 3 months prior to screening w8m-mc-cwmm: * have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) exclusion criteria: w8m-mc-laa2 * have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * have an on-going or history of bradyarrhythmia and/or sinus bradycardia * have an elevated resting pulse rate (mean \>100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening * have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * have renal impairment measured as estimated glomerular filtration rate (egfr) \<45 milliliters per minute (ml/min)/1.73 m2 * have a history of acute or chronic pancreatitis * have fasting triglycerides \>500 milligrams per deciliter (mg/dl) (5.7 mmol/l) at screening * all concomitant medications should be at a stable dose for at least 3 months prior to screening w8m-mc-cwmm * have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * have poorly controlled hypertension. * have a history of symptomatic gallbladder disease within the past 2 years * have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * have a lifetime history of suicide attempts.

Keywords: type 2 diabetes
musicotherapy in reducing peroperative anxiety and post-surgical pain in dental care

Conditions: Dental Pain and Sensation Disorders

Summary: the main purpose of musanx study is to highlight analgesic effectiveness of musicotherapy in post-surgical periodontal and implant; and to measure its per-operative anxiolytic effectiveness

this study will be on music use as musicotherapy "receptive " or " passive ", using hearing aid for listening in order to relax and reduce the anxiety and pain state of the patient. this care will be focused on the acute stress and pain during the dental care. another major secondary purpose will consist to explore the anxiolytic effect of the musicotherapy on diverse stress markers such as heart rate, respiratory rate, salivary cortisol ratio and electro-dermal intensity (red).

Eligibility criteria:
inclusion criteria: * majors aged between 18 and 55 years, with an appropriate hearing and able to use music-care© (selection of the playlist via internet access), * needing treatment in odontology - periodontal surgery (coronary elongation or sanitation surgery or muco-gingival surgery) or implantary surgery (placement of an unit implant or two implant in the same localization), * oral and dated consent, * agreeing to be contacted via phone at j+1 and to fill follow-up study documents, * profiting of social security or cmu. exclusion criteria: * patients with a long-term taking of anxiolytic or analgesic, * regular consumer of soft drug (cannabis) or hard drug (opioid), * patient with medical history of psychiatry (mental harm), hearing problem, cognitive and behavioural impairment (claustrophobia), sensory disabilities, * patient with problems of hemostasis, * majors under trusteeship or guardianship, * pregnant women or lactating, * minors, * protected person, deprived of freedom or under justice safeguard, * profiting of a medical help from government (ame), * not contactable after care, * patient with hepatic impairment, * patient with dry mouth, * patient relevant a suboptimal hearing incompatible with musicotherapy or inability to use music-care®.
ligamentoplasty of ligamentum tere developmental dysplasia of the hip

Conditions: Orthopedic Disorder

Summary: the hip is formed by the acetabulum, the proximal femur and soft tissues joining them (capsule, teres ligament, transverse ligament and pulvinar). the acetabulum is a complex structure in the growing child. it is formed by the joined pubis, this junction is called tri radiate cartilage, which is responsible for acetabular growth. the external surface of the acetabulum is covered by a horse shoe-shaped articular cartilage. the transverse ligament joins both extremes of the articular cartilage inferiorly.


Eligibility criteria:
inclusion criteria: * patient with developmental dysplasia of the hip (ddh) with : * age: from 9 months -3 years old. * virgin ddh. * failed closed reduction in the management of ddh. * failed open reduction through medial approach in the management of ddh. exclusion criteria: * • paralytic hip dislocation . * post septic hip dislocation. * traumatic hip dislocation . * age : below 9 months or above 5 years. * refusal to participate in this study.